Welcome & Introduction

Optimizing Treatment for First-line NSCLC

Personalized Therapy to Further Improve Outcomes in Patients with Braf Mutated mNSCLC

Evolving role of Immunotherapy in ES-SCLC

Panel Discussion - Achieving Dramatic Insights into Molecular Oncology & Precision Medicine of NSCLC MTB

Panel Discussion - Management of Early Lung Cancer

Real World Evidence Osimertinib as SoC ithe management of EGFRm NSCLC

Surgery After NACT in Locally Advanced Lung Cancer

Radiation in Locally Advanced Lung Cancer

Concurrent Chemotheprapy in Non-Small Cell Lung Cancer

Hidden EGFR Threats and Role of Amivantamab

Panel Discussion

Welcome

The importance of Thinking Holistically when caring for Head and Neck Patients

reviews

Osimertinib vs Dacomitinib

First line TKI+ something in EGFR mutated Lung Cancer

Osimertinib resistance mechanisms

Walk the first Line Management of Alk Positive NSCLC

Panel Discussion - Management of First-Line ALK-Rearranged NSCLC

Selection of 1st line therapy for MET amplification and MET Exon 14 mutation in NSCLC

Metastatic ROS I Positive Non Small Cell Lung Cancer

Panel Discussion - Management of Uncommon EGFR Mutations

Selection Of first Line Therapy for Exon 20 Insertion

Interpretation of PD1 MSI TMB in NSCLC

Slection of 1st line Immunotherapy in PDL1 Negative and non driver mutations-mNSCL-ca

Biomarkers for efficacy with immunotherapy

Closing Remarks

Optimizing Treatment for First-line NSCLC

Personalized Therapy to Further Improve Outcomes in Patients with Braf Mutated mNSCLC

Evolving role of Immunotherapy in ES-SCLC

Panel Discussion - Achieving Dramatic Insights into Molecular Oncology & Precision Medicine of NSCLC MTB

Panel Discussion - Management of Early Lung Cancer

Real World Evidence Osimertinib as SoC ithe management of EGFRm NSCLC

Surgery After NACT in Locally Advanced Lung Cancer

Radiation in Locally Advanced Lung Cancer

Concurrent Chemotheprapy in Non-Small Cell Lung Cancer

Hidden EGFR Threats and Role of Amivantamab

Panel Discussion

The importance of Thinking Holistically when caring for Head and Neck Patients

Osimertinib vs Dacomitinib

First line TKI+ something in EGFR mutated Lung Cancer

Osimertinib resistance mechanisms

Walk the first Line Management of Alk Positive NSCLC

Panel Discussion - Management of First-Line ALK-Rearranged NSCLC

Selection of 1st line therapy for MET amplification and MET Exon 14 mutation in NSCLC

Metastatic ROS I Positive Non Small Cell Lung Cancer

Panel Discussion - Management of Uncommon EGFR Mutations

Selection Of first Line Therapy for Exon 20 Insertion

Interpretation of PD1 MSI TMB in NSCLC

Slection of 1st line Immunotherapy in PDL1 Negative and non driver mutations-mNSCL-ca

Biomarkers for efficacy with immunotherapy